Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Bachina, Srinivas
Astrazeneca plc
(
M-006
)
Risk Based Validation Strategy for Pharmacometric Analysis Ready Dataset to improve efficiency and effectiveness
Srinivas Bachina
Favorite
Balthasar, Martha
University of North Carolina at Chapel Hill
(
T-050
)
A Mechanistic Pharmacokinetic-Pharmacodynamic Model Framework for Degrader-Antibody Conjugates
Martha Balthasar
Favorite
Bamgboye, Adeboye
University of Minnesota
(
T-070
)
Development and External Validation of a Machine Learning Model to Predict Clearance in Patients with Epilepsy and Migraine Receiving Intravenous Topiramate with or without Enzyme-Inducing Comedications
Adeboye Bamgboye
Favorite
Barbarossa, Maria Vittoria
Abbvie
(
S-056
)
Quantitative Assessment of Glecaprevir and Pibrentasvir Exposures in Adults with Chronic or Acute HCV Infection: A Comprehensive Analysis of Phase 2 and 3 Studies Utilizing Subject Matching and Population PK Simulations
Maria Vittoria Barbarossa
Favorite
Basu, Sanchita
Bristol Myers Squibb
(
M-046
)
Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation
Sanchita Basu
Favorite
Bathena, Sai Praneeth
Bristol Myers Squibb
(
M-008
)
Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
Sai Praneeth Bathena
Favorite
Battista, Christina
Simulations Plus
(
T-096
)
Enabling Earlier Predictions of Hepatotoxic Risk with Quantitative Structure-Activity Relationship-Machine Learning (QSAR-ML) and Quantitative Systems Toxicology (QST) Models
Christina Battista
Favorite
Bazzazi, Hojjat
Moderna Inc
(
M-079
)
Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model
Hojjat Bazzazi
Favorite
Bedathuru, Dinesh
Vantage Research Inc
(
S-017
)
Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model
Dinesh Bedathuru
Favorite
(
T-008
)
Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS
Dinesh Bedathuru
Favorite
Bender, Brendan
Genentech, Inc
(
S-117
)
Predicting Clinical Mosunetuzumab CD20 Receptor Occupancy using a Minimal Physiologically–Based Pharmacokinetic (mPBPK) Modeling Approach
Brendan Bender
Favorite
Bhasi, Kavitha
C4 Therapeutics, Inc.
(
M-095
)
Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Kavitha Bhasi
Favorite
Bishop, Corey
Johnson & Johnson
(
T-103
)
A Fisher Information Matrix-based Analysis to Determine Precision of Estimated PK Parameters for Reduced Sample Sizes in Pediatric Studies in Rare Diseases
Corey Bishop
Favorite
Biswas, Sujit
Pfizer Inc.
(
M-054
)
Population pharmacokinetics and exposure-safety analysis of SGN-STNV (PF-08046055) in patients with locally advanced and/or metastatic solid tumors: Phase-1a/b study
Sujit Biswas
Favorite
Boivin-Champeaux, Clémence
University of Florida
(
S-062
)
Development of a Quantitative Systems Pharmacology Model for Hepatitis B Virus Infection and Hepatitis D Virus Co-Infection.
Clémence Boivin-Champeaux
Favorite
Boras, Britton
(
T-066
)
QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations
Britton Boras
Favorite
Borek, Bartłomiej
Vertex Pharmaceuticals Inc
(
M-032
)
Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
Bartłomiej Borek
Favorite
Bosley, James
Nova in silico
(
M-019
)
In silico validation of MARIPOSA trial outcomes in EGFR‑mutated NSCLC using a QSP‑based disease model integrated with a newly implemented lazertinib drug model
James Bosley
Favorite
Bozenhardt, Emily
J&J Innovative Medicine
(
S-071
)
Assessment of Virtual Control Groups for Organ Impairment Studies Using Population Pharmacokinetic Simulation: Twin Matching versus Group Matching
Emily Bozenhardt
Favorite
Braniff, Nathan
Pfizer
(
T-071
)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Lorlatinib-treated Patients with Non-small Cell Lung Cancer
Nathan Braniff
Favorite
Brooks, Jordan
InsightRX
(
M-050
)
Real-world Performance Assessment and Model Re-evaluation in Children and Adults
Jordan Brooks
Favorite
Burton, Jackson
Biogen
(
M-111
)
Exposure-Response Relationship Between Litifilimab and Clinical Outcomes in Systemic Lupus Erythematosus Populations
Jackson Burton
Favorite
Buyukozturk, Fulden
Amgen
(
T-028
)
A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Fulden Buyukozturk
Favorite
